International Application Number:
`
`Confirmation Number:
`
`5508
`
`Title of Invention:
`
`OPHTHALMIC COMPOSITION
`
`Electronic AcknowledgementReceipt
`
`Application Number:
`
`16908426
`
`
`
`a
`
`Paymentinformation:
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpaymentas follows:
`
`
`
`File Listing:
`
`Pages
`Multi
`File Size(Bytes)/
`DocumentDescription
`Document
`
`
`
`Number Message Digest|Part/.zip|P (if appl.)
`330624
`
`1
`
`46682-701_317_IDS.pdf
`
`458054d003ddfe9a7560ecd04133d7c1 3de
`12de7
`
`Multipart Description/PDF files in .zip description
`
`Information:
`
`pe
`pe
`pe
`
`Information Disclosure Statement (IDS) Form (SB08)
`
`Information:
`
`Foreign Reference
`
`WO2014182620A1_EFS.PDF
`
`Information:
`
`1371882
`
`93509ef8f244e1 ddf89505bbd23 17ae5 186
`9252e
`
`256300
`
`NonPatentLiterature
`
`AKORN_ATROPINECARE_PROD
`UCTLABE_REVISED_2014.PDF 148c8ecb7f0a71dce81 2698ed0aa5673f3d4
`6053
`
`Information:
`
`Non Patent Literature
`
`AKORN_ATROPINECARETM_AU
`G2011_REV.PDF
`
`5169816de4251743174c9al fc7add7e95453}
`0387
`
`252657
`
`Information:
`
`Non Patent Literature
`
`AKRON_ATROPINECARETM_JU
`N2008_REV.PDF
`
`3d849cca1d208a12b8743949a5fe24427c
`96114
`
`138373
`
`
`
`Non Patent Literature
`
`APPLICATION_NUMBER_20628
`9ORIG1SO00_SUMMARY_REVIE
`W.PDF
`
`14d2d53c1b23c0e8508ec83517e015a53e5
`1ca94
`
`954162
`
`Non Patent Literature
`
`DECLARATION_OFSTEPHENBYR
`N_US10842787_29DEC2021.
`PDF
`
`6efd5933b1db3a19d7279265939f10e22c2|
`76a02
`
`3263475
`
`3131842
`
`DECLARATIONOFSTEPHENBYR
`N_US10888557_7JAN2022.PDF cbb3ddbd4c44c38a233448324adea46962|
`b6141
`
`4ffs5S
`
`Information:
`
`So
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`po
`
`Information:
`
`Information:
`
`Non Patent Literature
`
`Non Patent Literature
`
`DECLARATIONOFSTEPHENBYR
`N_US10940145_7JAN2022.PDF 77d83cc8183c5f354eca1469658433ee21
`1383
`
`6905681
`
`Non Patent Literature
`
`DRUGS_FDA_FDA-APPROVED-
`DRUGS-AKORNNDA206289.PDH 1355987162fda30429bfd4ad5658d502e5c|
`2d058
`
`294930
`
`Non Patent Literature
`
`FLETCHER_THEEFFECTOFSOLU
`TION_17-21.PDF
`
`52498763 16a2b374f1 cOf30d20d8b3fd25
`d7dbf
`
`455662
`
`Non Patent Literature
`
`MAIR_THEDETECTIONOFATROP
`INE_101-104.PDF
`
`fed18520a524b02b4f409d49f9891 ebcb3b
`
`230728
`
`
`
`fd6
`
`UNKNOWN_MODERNPHYSICA
`ORGANICCHEMISTRY_ZHIHU_2
`020.PDF
`
`Non Patent Literature
`
`2656237
`
`A0fcf07b6e633db35891 dbc37450892f818
`a62b
`
`12953202
`
`Non Patent Literature
`
`PARMAR_THESOLUTIONSOLID
`STATE_730-740.PDF
`
`€38416575f6ed2dcffe6c307fe2a79ad7 350
`b55a
`
`1313782
`
`Non Patent Literature
`
`SCHUBERT_STERILITYOFANEST
`HETIC_634-636.PDF
`
`9de5 1 7af9f37caf7656786943b7e3671a640}
`9615
`
`341356
`
`Non Patent Literature
`
`753157
`
`TAYLOR_A-CRITICAL-
`APPRAISAL-OF-DRUG-
`STABILITY_177-180.PDF
`
`ed5a32e7b2d7c99adec01e2d0936e1ca5dd
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_1-1.PDF
`
`76787b556db4a3238c629024b0578ac540q
`bb9e4
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_1-2.PDF
`
`00bdbbacc8b11a1b9b1 2af323c4dfb815b4}
`6d126
`
`13410666
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_2-1.PDF
`
`§2c3c5f09ed9d9666f850691f8561fdfl ba
`
`11708386
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`
`
`Non Patent Literature
`
`14906349
`
`ed3925880397f50d61de0c20beacOfceSda
`doiid
`
`13458017
`
`USPN10842787_FILEHISTORY_
`PART_2-2.PDF
`
`A0fa
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_3-1.PDF
`
`1d0e3659f76ccb31b61e06b35767344b5bd)
`2ccbd
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_3-2.PDF
`
`9c4960ea04ee9d72381d84536/61c9a6e7.
`80c5
`
`13686905
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_4-1.PDF
`
`4723f09dbc26fbc20b59861 cbe67flc7460al
`5384
`
`13099613
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_4-2.PDF
`
`9d23f85fb29b661215bc1 3efac5e32f1656c|
`8d8a
`
`13642590
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_5-1.PDF
`
`2a8df9d72f722361712e3f34627212d4cc71
`9ad9
`
`10947489
`
`Non Patent Literature
`
`USPN10842787_FILEHISTORY_
`PART_5-2.PDF
`
`1014cf5e2a7acd99eaff34b02c2e8b15b01a
`
`10528548
`
`
`
`27
`
`.
`Non Patent Literature
`
`USPN10842787_PETINTERPAR
`ESREVIEW_20DEC2021.PDF
`
`Information:
`
`4228323
`
`d9275ca2230ecSa9e321d20729ada0e1d27|
`Off32
`
`24060412
`
`Information:
`
`USPNTOBEESS7IPR_ZIAN2022 b2b420636f5cbe1d4b8eS 1659cde442f2a0
`
`28
`
`.
`Non Patent Literature
`
`USPN10888557_FILEHISTORY_
`PART_1.PDF
`
`05d6af03deb93d0fc247d0c89d684083c37
`48529
`
`Information:
`
`29
`
`.
`Non Patent Literature
`
`USPN10888557_FILEHISTORY_
`PART_2.PDF
`
`Information:
`
`24098674
`
`d87fdde977a184164e8e5d50a592fe9f60aa
`f88f
`
`24062251
`
`30
`
`.
`Non Patent Literature
`
`USPN10888557_FILEHISTORY_
`PART_3.PDF
`
`724cbdf82a2ad2b73cl d38ffad2c556a3c83}
`e160
`
`Information:
`
`31
`
`.
`Non Patent Literature
`
`USPN10888557_FILEHISTORY_
`PART_4.PDF
`
`Information:
`
`32
`
`.
`Non Patent Literature
`
`USPN10888557_FILEHISTORY_
`PART_5.PDF
`
`Information:
`
`24095770
`
`ad41527a082cb2672ea5b31 7aa35fb27796|
`b818c
`
`16049256
`
`506d99e46e8837b21d4b98555c5bacf0Se2}
`abda4
`
`3981030
`
`33
`
`Non PatentLiterature
`
`16467
`
`
`
`Non Patent Literature
`
`12953202
`
`$b12d11c38b85dd4aec395a5dd091 cO8bf6
`274dd
`
`13410670
`
`USPN10940145_FILEHISTORY_
`PART_1-1.PDF
`
`4f3d5
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Information:
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_1-2.PDF
`
`§27d156b725085e288d39787d0f0065b39|
`Saa22
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_2-1.PDF
`
`40a07199f17d37368396f980deba3810cb8,
`6f0f2
`
`11708386
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_2-2.PDF
`
`6b9783bda6d226069fbc8179d9f85408bbe}
`Aebd7
`
`14906349
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_3-1.PDF
`
`5f479b6113555a64d 1 12a5632f05a4a48134
`baS4
`
`13458017
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_3-2.PDF
`
`3aa38f94028a84ab74d4f2b9ff2b2d00eff9F|
`ade
`
`13686905
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_4-1.PDF
`
`8494a4f2aba787dd 1 36eb04eba4a7793287|
`
`13099613
`
`
`
`39cf6
`
`e I
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_4-2.PDF
`
`f0dba24133cded84936aa26c508fe8d0095q
`
`13642586
`
`Non Patent Literature
`
`USPN10940145_FILEHISTORY_
`PART_5-2.PDF
`
`3e7ffc9c852341c1291 9fe8b88a6a39a7816
`8757
`
`10528547
`
`3924710
`
`527ebb69b61d2c99b7d676874ee8941885
`30497
`
`683072
`
`§7001ec5f8266623d0763dbe0a59a01 ba40}
`fb995
`
`536808
`
`b82e5aea2e7f3079193eb9c2f4e84b8c58e4
`a340
`
`2257614
`
`Non Patent Literature
`
`USPN10940145_IPR_7JAN2022,
`PDF
`
`Non Patent Literature
`
`US16765144_OA_29MARCH20
`22.PDF
`
`Non Patent Literature
`
`US16785411_OA_24JAN2022.
`PDF
`
`Non Patent Literature
`
`USP_24OFFICIALMONOGRAP
`HS_ATROPINE_2000.PDF
`
`85174462582bc7ae2335c7e36fcd41b0756
`Acdb4
`
`Non Patent Literature
`
`YOSHIOKA_STABILITYOFDRUG
`SANDDOSAGEFORMS_2002.
`PDF
`
`74876f10b91 66bed4654042dc96cf42c2c
`
`18182070
`
`pe
`
`Information:
`
`Information:
`
`Information:
`
`nformation:
`
`e I
`
`nformation:
`
`Information:
`
`pe
`
`Information:
`
`
`
`48
`
`.
`Non Patent Literature
`
`ZHOU_CHAPTER-5_DRUGSTABI
`LITY_87-124.PDF
`
`2cf18c59369e27acf1 90aa280291a0e147bb|
`6987
`
`4280358
`
`Information:
`
`49
`
`.
`Non Patent Literature
`
`USPN10940145_FILEHISTORY
`—
`-
`PART_5-1.pdf
`
`975e8c3543378eed 1d765b4b7c09a5fe930|
`7Af87
`
`12076639
`
`3
`
`8
`
`20
`
`10
`
`2
`
`the application.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish the filing date of the application.
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903indicating acceptanceof the application as a
`national stage submission under35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`Information:
`
`50
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`934114775f7d404629928677aa4871763b3
`a8af3
`
`Information:
`
`This AcknowledgementReceipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`
